GlassScriptPhysician profile
Vasavi Malineni
NPI 1720037229
$6,809.84
in general payments reported to CMS, 2019-2025
22 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $345 · 2021: $317 · 2022: $537 · 2023: $3,090 · 2024: $1,031 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,641 · Travel and Lodging: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.33 |
| Travel and Lodging | $1,498.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,817.59 | 2022-2025 | |
| Carl Zeiss Meditec USA, INC. | $1,677.41 | 2023 | Veracity Surgical, Iolmaster 700, Cirrus Hd-Oct |
| Allergan, INC. | $685.87 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $642.95 | 2023-2025 | Catalys System, Tecnis Iol |
| Bausch & Lomb Americas INC. | $350.39 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $328.14 | 2019-2025 | Tryptyr, Rocklatan, Simbrinza |
| Novartis Pharmaceuticals Corporation | $263.00 | 2019-2023 | |
| Glaukos Corporation | $170.34 | 2023 | |
| Sun Pharmaceutical Industries INC. | $167.13 | 2020-2025 | Cequa |
| Biotissue Holdings INC. | $128.58 | 2024 | |
| Shire North American Group INC | $110.18 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $109.15 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.44 | 2019-2021 | |
| Ocular Therapeutix, INC. | $67.79 | 2023 | Dextenza |
| Harrow Eye, LLC | $53.01 | 2024-2025 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $33.55 | 2020 | |
| Thea Pharma INC. | $22.72 | 2023 | |
| Sight Sciences, INC. | $22.67 | 2024 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $21.11 | 2019 | |
| Dompe US, INC. | $19.66 | 2019 | |
| Eyevance Pharmaceuticals LLC | $17.54 | 2019 | |
| Quidel Corporation | $10.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasavi Malineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.